Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing

This article was originally published in The Tan Sheet

Executive Summary

FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales

Related Content

Gedeon Richter To Market HRA Pharma’s Novel Emergency Contraceptive, ellaOne
FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
FDA Will Accept Behind-The-Counter NDAs While Mulling “Continuum” Class
Plan B Plaintiffs Expect to Face Court’s “Huge Deference” To FDA
Behind-The-Counter Sale Works Without Regulation – Former FDA Counsel
N.Y. covers OTC Plan B
Viagra Non-Prescription Switch Would Face High Bar For Safety
Barr Takes CARE To Monitor Plan B Consumer Behavior Trends
CDER Officials Testify On Behind-The-Scenes Maneuvers In Plan B Rejection





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts